(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 3.19% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 9.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Amgen's revenue in 2026 is $36,751,000,000.On average, 36 Wall Street analysts forecast AMGN's revenue for 2026 to be $20,798,309,036,850, with the lowest AMGN revenue forecast at $19,728,259,701,975, and the highest AMGN revenue forecast at $21,899,085,229,200. On average, 33 Wall Street analysts forecast AMGN's revenue for 2027 to be $21,315,274,937,175, with the lowest AMGN revenue forecast at $19,568,695,670,175, and the highest AMGN revenue forecast at $24,178,802,426,775.
In 2028, AMGN is forecast to generate $21,749,763,483,225 in revenue, with the lowest revenue forecast at $19,300,779,035,700 and the highest revenue forecast at $23,791,212,768,450.